Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
09:45am, Thursday, 03'rd Apr 2025
Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025.
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
03:25pm, Monday, 31'st Mar 2025
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
04:53am, Monday, 31'st Mar 2025
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
Why Summit Therapeutics Stock Slipped Today
05:21pm, Wednesday, 26'th Mar 2025
Summit Therapeutics (SMMT -2.25%) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more
Summit Therapeutics upgraded ahead of lung cancer trial data readout
12:08pm, Wednesday, 26'th Mar 2025
Summit Therapeutics PLC (NASDAQ:SMMT) has been upgraded to a ‘Buy' rating by Citi analysts who are optimistic about the company's HARMONi-2 trial of ivonescimab in non-small cell lung cancer. Citi
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
02:17pm, Monday, 24'th Mar 2025
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Is Summit Therapeutics a Millionaire Maker?
05:49am, Sunday, 23'rd Mar 2025
Multiple paths to immense wealth exist. A few lucky people win the lottery.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 21'st Mar 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
This Unstoppable Biotech Stock Just Became an Even Better Buy
09:00am, Wednesday, 19'th Mar 2025
Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
04:24pm, Monday, 17'th Mar 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Comm
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 14'th Mar 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Why Summit Therapeutics Stock Was Winning This Week
08:13am, Friday, 14'th Mar 2025
A very bullish analyst move was the news generally responsible for Summit Therapeutics' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
07:30am, Thursday, 13'th Mar 2025
Summit Therapeutics (SMMT 7.62%) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the st
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer
09:40am, Tuesday, 25'th Feb 2025
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a
